Fatty liver disease (MASLD/MASH): open trials in Canada

18 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT06215716
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Trial Treatment · Phase 3 · Akero Therapeutics, Inc
Edmonton · Hamilton · Montreal · Terrebonne · Toronto · Vaughan
Registry updated 2026-11-06
NCT06632444
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Trial Treatment · Phase 3 · Boehringer Ingelheim
Viable Clinical Research, Bridgewater · University Of Calgary, Calgary · Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal · McGill University Health Centre (MUHC), Montreal · Diex Recherche Québec, Québec · Centre de Medecine Metabolique de Lanaudiere, Terrebonne · Toronto Liver Centre, Toronto · Pacific Gastroenterology Associates, Vancouver · University of British Columbia, Vancouver
Registry updated 2026-10-28
NCT06632457
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Trial Treatment · Phase 3 · Boehringer Ingelheim
Viable Clinical Research, Bridgewater · University Of Calgary, Calgary · McGill University Health Centre (MUHC), Montreal · Diex Recherche Québec, Québec · Toronto Liver Centre, Toronto · University of British Columbia, Vancouver
Registry updated 2026-10-28
NCT06318169
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Trial Treatment · Phase 3 · Hoffmann-La Roche
Calgary · London · Ottawa · Toronto · Vancouver · Vaughan · Winnipeg
Registry updated 2026-10-23
NCT06419374
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Trial Treatment · Phase 3 · Hoffmann-La Roche
Calgary · London · Ottawa · Toronto · Vancouver · Vaughan · Winnipeg
Registry updated 2026-10-23
NCT07325526
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
Trial Treatment · Phase 2 · Boehringer Ingelheim
University of Alberta Hospital (University of Alberta), Edmonton
Registry updated 2026-10-14
NCT06528314
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Trial Treatment · Phase 3 · Akero Therapeutics, Inc
Edmonton · Montreal · Terrebonne · Toronto · Vaughan
Registry updated 2026-10-13
NCT07165028
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Trial Treatment · Phase 3 · Eli Lilly and Company
Heritage Medical Research Clinic, Calgary · Ecogene-21, Chicoutimi · University of Alberta Hospital, Edmonton · Wells Research Group, Edmonton · QEII Health Sciences Centre, Victoria General Site, Halifax · University Hospital - London Health Sciences Centre, London · Private Practice - Dr. Stephane M. Gauthier, North Bay · Diex Recherche Québec, Québec · Clinical Research of Ontario, Toronto · Toronto General Hospital, Toronto · St. Joseph's Health Centre, Toronto · Diex Recherche Inc. Division Trois-Rivieres, Trois-Rivières · Vancouver General Hospital, Vancouver · (G.I.R.I.) GI Research Institute Foundation, Vancouver · Health Sciences Centre Winnipeg, Winnipeg
Registry updated 2026-10-08
NCT03572465
Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
Research · Centre hospitalier de l'Université de Montréal (CHUM)
Centre Hospitalier de l'Université de Montréal, Montreal
Registry updated 2026-09-16
NCT07335601
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Trial Treatment · Phase 2 · Madrigal Pharmaceuticals, Inc.
University Health Network - Toronto General Hospital (TGH), Toronto
Registry updated 2026-08-26
NCT06374875
Fibrosis Lessens After Metabolic Surgery
Trial Treatment · Phase 4 · The Cleveland Clinic
McGill University, Montreal
Registry updated 2026-07-31
NCT07221227
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Trial Treatment · Phase 3 · GlaxoSmithKline
Québec
Registry updated 2026-07-27
NCT06843148
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
Trial Treatment · Université de Sherbrooke
Centre de recherche du CHUS, Sherbrooke
Registry updated 2026-07-02
NCT05884723
Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis
Trial Treatment · Anton Skaro
London Health Sciences Centre/Western University, London
Registry updated 2026-05-19
NCT06694935
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
Trial Treatment · Phase 1 · 1Globe Health Institute
Centricity Research Toronto LMC., Toronto
Registry updated 2025-01-13
NCT06764056
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Trial Treatment · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec
Registry updated 2025-01-08
NCT06704321
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
Trial Treatment · Valbiotis
Institut sur la nutrition et les aliments fonctionnels - INAF, Québec
Registry updated 2024-11-26
NCT05480696
Soluble Fibre Supplementation in NAFLD
Trial Treatment · Phase 2 · McMaster University
McMaster University Medical Center, Hamilton
Registry updated 2024-11-12

All Fatty liver disease (MASLD/MASH) trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error